This is a working overview of Research chemical, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-06-04. Anything still debated is marked as such rather than presented as settled.
Regulatory bodies treat GW501516 as a prohibited substance in competitive sport. The World Anti-Doping Agency added it to the prohibited list, and it falls under classes covering metabolic modulators and hormone-related agents. It is not approved by drug regulators for human use, and it is not a lawful dietary supplement. Products sold under the cardarine name may contain unlisted ingredients or different compounds. Because no approved product exists, quality and identity are not guaranteed by pharmaceutical manufacturing standards.
Cardarine is a common name for the investigational chemical GW501516, also written GW-1516. It was developed as a peroxisome proliferator-activated receptor delta agonist for metabolic conditions such as dyslipidemia. Early research focused on lipid handling and energy use in skeletal muscle and other tissues. The compound was never approved as a medicine. In public discussion, it is often grouped with performance-enhancing substances, although its receptor target differs from that of anabolic steroids or selective androgen receptor modulators. Regulatory and health authorities have issued warnings about its use.
In the fitness and bodybuilding literature, cardarine is frequently discussed as an endurance agent or fat-loss compound, although such claims are not supported by robust clinical evidence. Online descriptions often mix animal data, user anecdotes, and marketing language. Researchers who study PPARδ agonists distinguish between receptor activation in controlled experiments and unsupervised use of unverified products. The latter introduces unknown purity, dose, and interactions, making reported experiences difficult to interpret scientifically.
GW501516 acts as an agonist at peroxisome proliferator-activated receptor delta, a nuclear receptor involved in transcription of genes related to lipid handling and energy use. Activation of PPARδ can shift skeletal muscle toward greater fatty acid oxidation in animal models, which is one reason it drew interest for metabolic disease and exercise research. The exact downstream effects depend on tissue, species, dose, and duration. Human data are sparse, so many proposed benefits remain hypotheses rather than established clinical outcomes.
Laboratory studies have examined GW501516 in cell cultures and rodents for conditions such as dyslipidemia, insulin resistance, and obesity. Some trials in humans were initiated, but development was discontinued after preclinical findings raised concerns about cancer in certain models. Those findings do not prove that the compound causes cancer in people, but they contributed to regulatory caution. Later reviews often describe the evidence as preliminary and insufficient for assessing long-term safety.
| Property | Value | Notes |
|---|---|---|
| Common name | Cardarine | Common internet and media name. |
| Research code | GW501516 | Also written GW-1516. |
| Drug class | PPARδ agonist | Not a selective androgen receptor modulator. |
| Development status | Discontinued | Clinical development halted after rodent cancer findings. |
| Regulatory status | Prohibited in sport | Listed by WADA; not approved as medicine. |
PPARδ is a nuclear receptor that regulates gene expression related to fatty acid oxidation, glucose homeostasis, and mitochondrial function. GW501516 binds to this receptor with high affinity and activates downstream signaling in skeletal muscle and other tissues. Animal studies reported increased endurance and altered fuel preference, but human data remain limited and inconsistent. The precise relationship between receptor activation and observed physiological changes is still an area of active investigation. Researchers have also examined whether the compound affects inflammation or cell proliferation. No approved therapeutic indication exists for cardarine.
In laboratory settings, cardarine is studied as a tool compound for probing PPARδ biology. Published experiments often use cell cultures, rodent models, or isolated tissues. Some investigations focus on metabolic effects, while others assess potential risks such as carcinogenicity observed in long-term animal studies. Because human trials are sparse, most knowledge comes from preclinical work and adverse event reports. Scientific literature frequently notes the gap between animal findings and human outcomes. The compound is not a dietary supplement and is not intended for human consumption.
Cardarine is a common name for GW501516, a synthetic compound developed in the 1990s through research collaborations involving GlaxoSmithKline. It belongs to a class of molecules known as peroxisome proliferator-activated receptor delta agonists. Early studies explored its effects on lipid metabolism and energy expenditure in animal models. The compound was never approved as a human medicine, and clinical development was discontinued. In the years since, it has appeared in fitness and bodybuilding communities as a performance-enhancing substance. Regulatory agencies classify it as an unapproved drug.
Cardarine can be detected in biological samples and product materials using liquid chromatography coupled to tandem mass spectrometry (LC-MS/MS). The method separates compounds by chromatography and identifies them by mass-to-charge transitions, allowing low-level detection in urine or blood. Sample preparation often involves enzymatic hydrolysis, solid-phase extraction, or protein precipitation. Certified reference materials and isotope-labeled internal standards improve quantification. Detection windows depend on metabolism, matrix, and assay sensitivity, so no single universal window applies.
Regulatory treatment of cardarine differs by context and jurisdiction. In competitive sport, the World Anti-Doping Agency lists PPARδ agonists, including GW501516, as prohibited at all times. Outside sport, it lacks approval as a prescription medicine in major drug markets, and products sold for human consumption may be treated as unapproved drugs. Some countries also restrict importation or sale through general consumer protection and medicines laws. These classifications affect availability, testing, and legal risk without establishing therapeutic value.
The pharmacological interest in cardarine centers on PPARδ activation and its downstream effects on lipid handling and mitochondrial function. In animal studies, PPARδ agonists have been associated with changes in exercise endurance and fatty acid utilization, though results vary by model and protocol. Human data remain sparse, and the absence of large controlled trials limits conclusions about efficacy. Researchers often describe the compound as a tool for probing PPARδ biology rather than a proven therapeutic agent.
Safety discussions about cardarine frequently cite rodent carcinogenicity findings reported in the 2000s. In those studies, treated animals developed tumors at multiple sites, leading sponsors to discontinue clinical development. The relevance of these findings to humans has not been resolved, but they are a major reason the compound is not approved. Current literature emphasizes uncertainty about long-term effects and the risks of unregulated use. Regulators and health agencies have not established a safe human exposure level.
Cardarine is a synthetic compound also known as GW501516, GW-501516, and sometimes endurobol. It was developed as a selective agonist of peroxisome proliferator-activated receptor delta, a nuclear receptor involved in fatty acid oxidation and energy metabolism. The compound was studied in preclinical models for metabolic and cardiovascular conditions, but it did not become a marketed human medicine. In regulatory and anti-doping contexts, it is treated as a prohibited substance rather than a licensed medicine.
Public health care services are available for transgender individuals in Spain, although there has been debate over whether certain procedures should be covered under the public system. The region of Andalusia was the first to approve sex reassignment procedures, including sex reassignment surgery and mastectomies, in 1999, and several other regions have followed their lead in the following years. Multiple interdisciplinary clinics exist in Spain to cater specifically to diagnosing and treating transgender patients, including the Andalusian Gender Team. As of 2013, over 4000 transgender patients had been treated in Spain, including Spaniards and international patients. Beginning in 2007, Spain has begun allowing transgender individuals who are eighteen years or older to change their name and gender identity on public records and documents if they have been receiving hormone replacement therapy for at least two years.
== Departments == Division of Basic Medical Sciences I Department of Biochemistry Department of General Biology Department of Medical Physics Division of Basic Medical Sciences II Department of Anatomy Department of General Pharmacology Department of Physiology Division of Clinical Laboratories Department of Microbiology Department of Nuclear Medicine Department of Pathology Department of Public Health Department of Radiology Division of Internal Medicine Ι Department of Internal Medicine Division of Paediatrics & Obstetrics – Gynaecology Department of Obstetrics - Gynecology Department of Paediatric Surgery Department of Paediatrics Division of Surgery Department of Anaesthesiology and Intensive Care Department of Cardiothoracic Surgery Department of Neurosurgery Department of Ophthalmology Department of Orthopaedics Department of Otorhinolaryngology Department of Surgery Department of Urology Department of Vascular Surgery
An oligopeptide (oligo-, "a few"), is a peptide consisting of two to twenty amino acids, including dipeptides, tripeptides, tetrapeptides, and other polypeptides. Some of the major classes of naturally occurring oligopeptides include aeruginosins, cyanopeptolins, microcystins, microviridins, microginins, anabaenopeptins, and cyclamides. Microcystins are best studied because of their potential toxicity impact in drinking water. A review of some oligopeptides found that the largest class are the cyanopeptolins (40.1%), followed by microcystins (13.4%).
In the context of these functional rearrangements, these tertiary or quaternary structures are usually referred to as "conformations", and transitions between them are called conformational changes. Such changes are often induced by the binding of a substrate molecule to an enzyme's active site, or the physical region of the protein that participates in chemical catalysis. In solution, protein structures vary because of thermal vibration and collisions with other molecules.
Animals are categorised into ecological groups depending on their trophic levels and how they consume organic material. Such groupings include carnivores (further divided into subcategories such as piscivores, insectivores, ovivores, etc.), herbivores (subcategorised into folivores, graminivores, frugivores, granivores, nectarivores, algivores, etc.), omnivores, fungivores, scavengers/detritivores, and parasites. Interactions between animals of each biome form complex food webs within that ecosystem. In carnivorous or omnivorous species, predation is a consumer–resource interaction where the predator feeds on another organism, its prey, who often evolves anti-predator adaptations to avoid being fed upon. Selective pressures imposed on one another lead to an evolutionary arms race between predator and prey, resulting in various antagonistic/competitive coevolutions. Almost all multicellular predators are animals. Some consumers use multiple methods; for example, in parasitoid wasps, the larvae feed on the hosts' living tissues, killing them in the process, but the adults primarily consume nectar from flowers. Other animals may have very specific feeding behaviours, such as hawksbill sea turtles which mainly eat sponges.
Sources: en.wikipedia.org
7.3.2.1 ABC-type phosphate transporter The expected taxonomic range for this enzyme is: Eukaryota, Bacteria. A bacterial enzyme that interacts with an extracytoplasmic substrate binding protein and mediates the high affinity uptake of phosphate anions. Unlike P-type ATPases, it does not undergo phosphorylation during the transport process. ATP + H2O + phosphate [phosphate - binding protein][side 1] = ADP + phosphate + phosphate [side 2] + [phosphate - binding protein][side 1] 7.3.2.2 ABC-type phosphonate transporter The enzyme, found in bacteria, interacts with an extracytoplasmic substrate binding protein and mediates the import of phosphonate and organophosphate anions. ATP + H2O + phosphonate [phosphonate-binding protein][side 1] = ADP + phosphate + phosphonate [side 2] + [phosphonate- binding protein][side 1] 7.3.2.3 ABC-type sulfate transporter The expected taxonomic range for this enzyme is: Eukaryota, Bacteria. The enzyme from Escherichia coli can interact with either of two periplasmic binding proteins and mediates the high affinity uptake of sulfate and thiosulfate. May also be involved in the uptake of selenite, selenate and possibly molybdate. Does not undergo phosphorylation during the transport. ATP + H2O + sulfate [sulfate - binding protein] [side 1] = ADP + phosphate + sulfate [side 2] + [sulfate - binding protein][side 1] 7.3.2.4 ABC-type nitrate transporter The expected taxonomic range for this enzyme is: Eukaryota, Bacteria.
Fascinated by the theories of Max Weber, Peukert began his last book with a quote from Weber who warned that the modern age would bring about "experts without spirit" and the "hedonist without a heart". Peukert went on to write about this modern age: "At its beginning there is immense loneliness and religious distress, which however help to bring about an unsuspected enhancement of the individual's attachment to this life, his rational control of the world and intellectual autonomy; at its end we may find routine "enslavement to the future", emptied of all meaning and causing the dynamic, expansive force of rationalization to ossify. In both cases, however, the growing pressure of suffering is the price paid for the gain in rationality". For Peukert, inspired by the theories of Weber, saw the purpose of his work to help foster experts who have spirit and hedonists with a heart.Though Peukert worked primarily as a historian (an occupation that has far greater prestige in Germany than it does in the English-speaking world), he also wrote about at times about literacy theory, philosophy, and anthropology. Peukert was also politically engaged, and his last essay written shortly before his death, Rechtsradikalismus in historischer Perspektive (Right-wing Radicalism in the Historical Perspective) warned against the rise of the party The Republicans led by the former SS-Unterscharführer Franz Schönhuber, which had some popular support in Germany with its call for a ban on Turkish "guest workers".
== Life and career == Eric M. Verdin was born in Belgium. He has a BS in Medical Sciences and doctorate of medicine from the University of Liege. After graduating from university, Verdin trained at Harvard Medical School. In 1997, he joined the Gladstone Institute for Virology and Immunology, where he worked for twenty years. He ended his time there as associate director and senior investigator in the virology and immunology unit. He is also a professor of medicine at the University of California, San Francisco. He previously held faculty positions at the National Institutes of Health and at Picower Institute for Medical Research. He is on the scientific advisory board of Amazentis and previously served on the National Scientific Advisory Council of the American Federation for Aging Research. He was a consultant to Calico, an aging-research company founded by Google. He is an inventor on at least 15 published patents. Verdin recreationally races race cars and trains for mental and physical endurance in LMP, Formula Atlantic and Formula 1 cars.
Murphree developing centrifuges, and Arthur Compton responsible for theoretical studies and design. On 23 April 1942, Met Lab scientists discussed seven possible ways to extract plutonium from irradiated uranium, and decided to pursue investigation of all seven. On 17 June, the first batch of uranium nitrate hexahydrate (UNH) was undergoing neutron bombardment in the Washington University in St. Louis cyclotron. On 27 July, the irradiated UNH was ready for Glenn T. Seaborg's team. On 20 August, using ultramicrochemistry techniques, they successfully extracted plutonium. In May 1942, Gertrude Scharff Goldhaber at Brookhaven National Laboratory reports for the first the emission of multiple neutrons during spontaneous fission of uranium. Her research was kept a secret. In April 1939, creating a chain reaction in natural uranium became the goal of Fermi and Szilard, as opposed to isotope separation. Their first efforts involved five hundred pounds of uranium oxide from the Eldorado Radium Corporation. Packed into fifty-two cans two inches in diameter and two feet long in a tank of manganese solution, they were able to confirm more neutrons were emitted than absorbed. However, the hydrogen within the water absorbed the slow neutrons necessary for fission. Carbon in the form of graphite, was then considered, because of its smaller capture cross section. In April 1940, Fermi was able to confirm carbon's potential for a slow-neutron chain reaction, after receiving National Carbon Company's graphite bricks at their Pupin Laboratories.
Sources: en.wikipedia.org
== Further reading == Müller, Bodo (2006). Coatings formulation: an international textbook. Urlich Poth. Hannover: Vincentz. ISBN 3-87870-177-2. OCLC 76886114. Spyrou, Emmanouil (2012). Powder coatings chemistry and technology (3 ed.). Vincentz Network. ISBN 978-3-86630-884-8. OCLC 828194496. Titanium and titanium alloys, edited by C. Leyens and M. Peters, Wiley-VCH, ISBN 3-527-30534-3, table 6.2: overview of several coating systems and fabrication processes for titanium alloys and titanium aluminides (amended) Coating Materials for Electronic Applications: Polymers, Processes, Reliability, Testing by James J. Licari; William Andrew Publishing, Elsevier, ISBN 0-8155-1492-1 High-Performance Organic Coatings, ed. AS Khanna, Elsevier BV, 2015, ISBN 978-1-84569-265-0
=== Lotion === Lotions are similar to solution but are thicker and tend to be more emollient in nature than the solution. They are usually oil mixed with water, and more often than not have less alcohol than solution. Lotions can be drying if they contain a high amount of alcohol.
In 1972, a Honeywell 316 was displayed with a semiconductor RAM memory board (they used core memory previously). It was never placed into production, as DTL was too power-hungry to survive much longer. Honeywell knew that the same technology that enabled the production of RAM spelled the end of DTL computers, and wanted to show that the company was cutting edge.
Sources: en.wikipedia.org
No. Cardarine is a PPARδ agonist, while selective androgen receptor modulators act on androgen receptors. The two classes differ in receptor target and downstream effects.
Preclinical rodent studies reported cancers, including liver and bladder tumors, at tested doses. The human relevance of those findings is uncertain, but development was discontinued. No approved human product resulted.
No. It remains an investigational compound without approved therapeutic labeling. Sports regulators prohibit its use, and health agencies have warned against consuming it.
It binds and activates PPARδ, a nuclear receptor that influences gene expression related to fatty acid metabolism and energy balance. This mechanism has been studied mainly in animals and cell models, not established as a safe human therapy.